In contrast to baseline expression, only IBD patients achieving clinical remission after anti-TNF treatment (n = 21; remission: UC = 7 and CD = 7; nonremission: CD = 1 and UC = 6) displayed a significant reduction of mucosal IL22, TNF, and MLKL mRNA expression, as well as the ISG score levels (Fig. 9 B). This evidence concerns the gene IL22 and inflammatory bowel disease.